Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes

Pharmacological Research

Volumn 119, Issue , 2017, Pages 195-207

  Campesi, Ilaria ^a   Franconi, Flavia ^a,b   Seghieri, Giuseppe ^c   Meloni, Marco ^d  

^a UNIVERSITY OF SASSARI   (Italy)

^b Dipartimento Politiche della Persona   (Italy)

^c Section Dermatology   (Italy)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cardiovascular complications; Diabetes mellitus; Risk factors; Sex gender differences; Therapeutic approaches

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN;

ALCOHOL CONSUMPTION; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTERMITTENT CLAUDICATION; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBESITY; OVARY POLYCYSTIC DISEASE; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREGNANCY DIABETES MELLITUS; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VASCULAR DISEASE; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; SEXUAL DEVELOPMENT;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; SEX CHARACTERISTICS; SEX FACTORS;

EID: 85012895003     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.01.023     Document Type: Review

References (282)

1. [1] Zimmet, P., Alberti, K.G., Shaw, J., Global and societal implications of the diabetes epidemic. Nature 414 (2001), 782–787.
2. [2] Zimmet, P., Alberti, K.G., Magliano, D.J., Bennett, P.H., Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat. Rev. Endocrinol. 12:10 (2016), 616–622.
3. [3] Gao, H.X., Regier, E.E., Close, K.L., International Diabetes Federation World Diabetes Congress 2015. J. Diabetes 8 (2016), 300–304.
4. [4] Anik, A., Catli, G., Abaci, A., Bober, E., Maturity-onset diabetes of the young (mody): an update. J. Pediatr. Endocrinol. Metab. JPEM 28 (2015), 251–263.
5. [5] Urano, F., Wolfram syndrome: diagnosis, management, and treatment. Curr. Diabetes Rep., 16, 2016, 6.
6. [6] Alvarez-Satta, M., Castro-Sanchez, S., Valverde, D., Alstrom syndrome: current perspectives. Appl. Clin. Genet. 8 (2015), 171–179.
7. [7] Liu, L., Li, X., Xiang, Y., Huang, G., Lin, J., Yang, L., Zhao, Y., Yang, Z., Hou, C., Li, Y., Liu, J., Zhu, D., Leslie, R.D., Wang, X., Zhou, Z., Group LCS, Latent autoimmune diabetes in adults with low-titer gad antibodies: similar disease progression with type 2 diabetes: a nationwide, multicenter prospective study (Lada China study 3). Diabetes Care 38 (2015), 16–21.
8. [8] Giuffrida, F.M., Reis, A.F., Genetic and clinical characteristics of maturity-onset diabetes of the young. Diabetes Obes. Metab. 7 (2005), 318–326.
9. [9] Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Circulation 100 (1999), 1132–1133.
10. [10] Chamberlain, J.J., Rhinehart, A.S., Shaefer, C.F. Jr., Neuman, A., Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann. Intern. Med. 164 (2016), 542–552.
11. [11] Stettler, C., Suter, Y., Allemann, S., Zwahlen, M., Christ, E.R., Diem, P., Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up. J. Intern. Med. 260 (2006), 272–280.
12. [12] Skyler, J.S., Bergenstal, R., Bonow, R.O., Buse, J., Deedwania, P., Gale, E.A., Howard, B.V., Kirkman, M.S., Kosiborod, M., Reaven, P., Sherwin, R.S., American Diabetes A, American College of Cardiology F, American Heart A, Intensive glycemic control and the prevention of cardiovascular events: implications of the accord, advance, and va diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119 (2009), 351–357.
13. [13] Marino, M., Masella, R., Bulzomi, P., Campesi, I., Malorni, W., Franconi, F., Nutrition and human health from a sex-gender perspective. Mol. Asp. Med. 32 (2011), 1–70.
14. [14] Franconi, F., Carru, C., Spoletini, I., Malorni, W., Vella, S., Mercuro, G., Deidda, M., Rosano, G., A gens-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. Ther. Deliv. 2 (2011), 1437–1453.
15. [15] Franconi, F., Campesi, I., Occhioni, S., Tonolo, G., Sex-gender differences in diabetes vascular complications and treatment. Endocr. Metab. Immune Disord. Drug Targets 12 (2012), 179–196.
16. [16] Franconi, F., Campesi, I., Sex and gender influences on pharmacological response: an overview. Expert Rev. Clin. Pharmacol. 7 (2014), 469–485.
17. [17] Seghieri, C., Policardo, L., Francesconi, P., Seghieri, G., Gender differences in the relationship between diabetes process of care indicators and cardiovascular outcomes. Eur. J. Public Health 26 (2016), 219–224.
18. [18] Recarti, C., Sep, S.J., Stehouwer, C.D., Unger, T., Excess cardiovascular risk in diabetic women: a case for intensive treatment. Curr. Hypertens. Rep., 17, 2015, 554.
19. [19] Huxley, R.R., Peters, S.A., Mishra, G.D., Woodward, M., Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 3 (2015), 198–206.
20. [20] Sattar, N., Gender aspects in type 2 diabetes mellitus and cardiometabolic risk. Best Pract. Res. Clin. Endocrinol. Metab. 27 (2013), 501–507.
21. [21] Franconi, F., Campesi, I., Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br. J. Pharmacol. 171 (2014), 580–594.
22. [22] Franconi, F., Seghieri, G., Canu, S., Straface, E., Campesi, I., Malorni, W., Are the available experimental models of type 2 diabetes appropriate for a gender perspective?. Pharmacol. Res. 57 (2008), 6–18.
23. [23] Wandell, P.E., Carlsson, A.C., Time trends and gender differences in incidence and prevalence of type 1 diabetes in Sweden. Curr. Diabetes Rev. 9 (2013), 342–349.
24. [24] Patterson, C., Guariguata, L., Dahlquist, G., Soltesz, G., Ogle, G., Silink, M., Diabetes in the young – a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res. Clin. Pract. 103 (2014), 161–175.
25. [25] Group, D.S., Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26 (2003), 61–69.
26. [26] Janghorbani, M., Amini, M., Effects of gender and height on the oral glucose tolerance test: the Isfahan diabetes prevention study. Rev. Diabet. Stud. RDS 5 (2008), 163–170.
27. [27] Ehtisham, S., Hattersley, A.T., Dunger, D.B., Barrett, T.G., British Society for Paediatric E, Diabetes Clinical Trials G, First UK survey of paediatric type 2 diabetes and mody. Arch. Dis. Child. 89 (2004), 526–529.
28. [28] Fagot-Campagna, A., Emergence of type 2 diabetes mellitus in children: epidemiological evidence. J. Pediatr. Endocrinol. Metab. JPEM 13:Suppl. 6 (2000), 1395–1402.
29. [29] Hirschler, V., Maccallini, G., Karam, C., Gonzalez, C., Aranda, C., Are girls more insulin-resistant than boys?. Clin. Biochem. 42 (2009), 1051–1056.
30. [30] Travers, S.H., Jeffers, B.W., Bloch, C.A., Hill, J.O., Eckel, R.H., Gender and tanner stage differences in body composition and insulin sensitivity in early pubertal children. J. Clin. Endocrinol. Metab. 80 (1995), 172–178.
31. [31] Ehtisham, S., Crabtree, N., Clark, P., Shaw, N., Barrett, T., Ethnic differences in insulin resistance and body composition in united kingdom adolescents. J. Clin. Endocrinol. Metab. 90 (2005), 3963–3969.
32. [32] Annamalai, A., Tek, C., An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists. International journal of endocrinology, 2015, 2015, 969182.
33. [33] Smith, M., Hopkins, D., Peveler, R.C., Holt, R.I., Woodward, M., Ismail, K., First- v. Second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry J. Ment. Sci. 192 (2008), 406–411.
34. [34] Chen, D.C., Zhou, M.A., Zhou, D.H., Xiu, M.H., Wu, G.Y., Kosten, T.R., Zhang, X.Y., Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics. Psychiatry Res. 186 (2011), 451–453.
35. [35] Zhang, B.H., Han, M., Zhang, X.Y., Hui, L., Jiang, S.R., Yang, F.D., Tan, Y.L., Wang, Z.R., Li, J., Huang, X.F., Gender differences in cognitive deficits in schizophrenia with and without diabetes. Compr. Psychiatry 63 (2015), 1–9.
36. [36] Anderson, R.J., Freedland, K.E., Clouse, R.E., Lustman, P.J., The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24 (2001), 1069–1078.
37. [37] Nichols, G.A., Brown, J.B., Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. Diabetes Care 26 (2003), 744–749.
38. [38] Andreoulakis, E., Hyphantis, T., Kandylis, D., Iacovides, A., Depression in diabetes mellitus: a comprehensive review. Hippokratia 16 (2012), 205–214.
39. [39] Egede, L.E., Effects of depression on work loss and disability bed days in individuals with diabetes. Diabetes Care 27 (2004), 1751–1753.
40. [40] Black, S.A., Markides, K.S., Ray, L.A., Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care 26 (2003), 2822–2828.
41. [41] Finkelstein, E.A., Bray, J.W., Chen, H., Larson, M.J., Miller, K., Tompkins, C., Keme, A., Manderscheid, R., Prevalence and costs of major depression among elderly claimants with diabetes. Diabetes Care 26 (2003), 415–420.
42. [42] de Groot, M., Anderson, R., Freedland, K.E., Clouse, R.E., Lustman, P.J., Association of depression and diabetes complications: a meta-analysis. Psychosom. Med. 63 (2001), 619–630.
43. [43] Ciechanowski, P.S., Katon, W.J., Russo, J.E., Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch. Intern. Med. 160 (2000), 3278–3285.
44. [44] Lin, E.H., Katon, W., Von Korff, M., Rutter, C., Simon, G.E., Oliver, M., Ciechanowski, P., Ludman, E.J., Bush, T., Young, B., Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 27 (2004), 2154–2160.
45. [45] Zhang, X., Norris, S.L., Gregg, E.W., Cheng, Y.J., Beckles, G., Kahn, H.S., Depressive symptoms and mortality among persons with and without diabetes. Am. J. Epidemiol. 161 (2005), 652–660.
46. [46] Grant, J.F., Hicks, N., Taylor, A.W., Chittleborough, C.R., Phillips, P.J., North West Adelaide Health Study T, Gender-specific epidemiology of diabetes: a representative cross-sectional study. Int. J. Equity Health, 8, 2009, 6.
47. [47] Seghieri, G., Policardo, L., Anichini, R., Franconi, F., Campesi, I., Cherchi, S., Tonolo, G., The effect of sex and gender on diabetic complications. Curr. Diabetes Rev., 2016 May 17. [Epub ahead of print].
48. [48] Meisinger, C., Thorand, B., Schneider, A., Stieber, J., Doring, A., Lowel, H., Sex differences in risk factors for incident type 2 diabetes mellitus: the Monica Augsburg cohort study. Arch. Intern. Med. 162 (2002), 82–89.
49. [49] Pan, X., Gender dissimilarity in type 2 diabetes risk factors: a Chinese study. Int. J. Behav. Med. 22 (2015), 614–624.
50. [50] Jones, T.H., Arver, S., Behre, H.M., Buvat, J., Meuleman, E., Moncada, I., Morales, A.M., Volterrani, M., Yellowlees, A., Howell, J.D., Channer, K.S., Investigators, T., Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the Times2 study). Diabetes Care 34 (2011), 828–837.
51. [51] Krysiak, R., Gilowska, M., Szkrobka, W., Okopien, B., The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and amiodarone-induced hypothyroidism. Pharmacol. Rep. PR 68 (2016), 490–494.
52. [52] Bahado-Singh, R.O., Mele, L., Landon, M.B., Ramin, S.M., Carpenter, M.W., Casey, B., Wapner, R.J., Varner, M.W., Rouse, D.J., Thorp, J.M. Jr., Sciscione, A., Catalano, P., Harper, M., Saade, G., Caritis, S.N., Peaceman, A.M., Tolosa, J.E., Eunice Kennedy Shriver National Institute of Child H, Human Development Maternal-fetal Medicine Units N, Fetal male gender and the benefits of treatment of mild gestational diabetes mellitus. Am. J. Obstet. Gynecol. 206:422 (2012), e421–425.
53. [53] Sojo, L., Garcia-Patterson, A., Maria, M.A., Martin, E., Ubeda, J., Adelantado, J.M., de Leiva, A., Corcoy, R., Are birth weight predictors in diabetic pregnancy the same in boys and girls?. Eur. J. Obstet. Gynecol. Reprod. Biol. 153 (2010), 32–37.
54. [54] Retnakaran, R., Shah, B.R., Fetal sex and the natural history of maternal risk of diabetes during and after pregnancy. J. Clin. Endocrinol. Metab. 100 (2015), 2574–2580.
55. [55] Moleda, P., Fronczyk, A., Safranow, K., Majkowska, L., Is uric acid a missing link between previous gestational diabetes mellitus and the development of type 2 diabetes at a later time of life?. PLoS One, 11, 2016, e0154921.
56. [56] Toulis, K.A., Goulis, D.G., Farmakiotis, D., Georgopoulos, N.A., Katsikis, I., Tarlatzis, B.C., Papadimas, I., Panidis, D., Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum. Reprod. Update 15 (2009), 297–307.
57. [57] Allalou, A., Nalla, A., Prentice, K.J., Liu, Y., Zhang, M., Dai, F.F., Ning, J.X., Osborne, L.R., Cox, B.J., Gunderson, E.P., Wheeler, M.B., A predictive metabolic signature for the transition from gestational diabetes to type 2 diabetes. Diabetes 65:9 (2016), 2529–2539.
58. [58] Berntorp, K.E., Gestational diabetes: what's up?. Diabetologia 59 (2016), 1382–1384.
59. [59] Kautzky-Willer, A., Harreiter, J., Pacini, G., Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr. Rev. 37 (2016), 278–316.
60. [60] Eades, C.E., Styles, M., Leese, G.P., Cheyne, H., Evans, J.M., Progression from gestational diabetes to type 2 diabetes in one region of scotland: an observational follow-up study. BMC Pregnancy Childbirth, 15, 2015, 11.
61. [61] American Diabetes A, Peripheral arterial disease in people with diabetes. Diabetes Care 26 (2003), 3333–3341.
62. [62] Clark, N., Sheehan, P., Edmonds, M., Januzzi, J.L., Regensteiner, J., Sanders, L., Sykes, M., Attinger, C.E., Beckman, J., Criqui, M., Froelich, J.B., Giurini, J.M., Haas, L., Hamdan, A., Harkless, L., Jaff, M.R., Jialal, I., LoGerfo, F., Mohler, E.R., Olin, J., Pinzur, M., Reiber, G.E., Rosenfield, K., Tesfaye, S., Veves, A., Yucel, E.K., Assoc, A.D., Peripheral arterial disease in people with diabetes. Diabetes Care 26 (2003), 3333–3341.
63. [63] Marso, S.P., Hiatt, W.R., Peripheral arterial disease in patients with diabetes. J. Am. Coll. Cardiol. 47 (2006), 921–929.
64. [64] Al-Delaimy, W.K., Merchant, A.T., Rimm, E.B., Willett, W.C., Stampfer, M.J., Hu, F.B., Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am. J. Med. 116 (2004), 236–240.
65. [65] Adler, A.I., Stevens, R.J., Neil, A., Stratton, I.M., Boulton, A.J., Holman, R.R., Ukpds 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 25 (2002), 894–899.
66. [66] Beckman, J.A., Creager, M.A., Libby, P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002), 2570–2581.
67. [67] Bild, D.E., Selby, J.V., Sinnock, P., Browner, W.S., Braveman, P., Showstack, J.A., Lower-extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care 12 (1989), 24–31.
68. [68] Lacroix, P., Aboyans, V., Medeau, L., Preux, P.M., Bertin, F., Cornu, E., Laskar, M., Long-term survival of elderly amputated vascular patients. Arch. Mal. Coeur Vaiss. 93 (2000), 1189–1193.
69. [69] Armstrong, D.G., Lavery, L.A., van Houtum, W.H., Harkless, L.B., The impact of gender on amputation. J. Foot Ankle Surg. 36 (1997), 66–69 discussion 81.
70. [70] Amin, L., Shah, B.R., Bierman, A.S., Lipscombe, L.L., Wu, C.F., Feig, D.S., Booth, G.L., Gender differences in the impact of poverty on health: disparities in risk of diabetes-related amputation. Diabet. Med. 31 (2014), 1410–1417.
71. [71] Davie-Smith, F., Paul, L., Nicholls, N., Stuart, W.P., Kennon, B., The impact of gender, level of amputation and diabetes on prosthetic fit rates following major lower extremity amputation. Diabet Med. 31:11 (2016), 1410–1417.
72. [72] Stein, B., Weintraub, W.S., Gebhart, S.P., Cohen-Bernstein, C.L., Grosswald, R., Liberman, H.A., Douglas, J.S. Jr., Morris, D.C., King, S.B. 3rd, Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91 (1995), 979–989.
73. [73] Droste, C., Roskamm, H., Experimental pain measurement in patients with asymptomatic myocardial ischemia. J. Am. Coll. Cardiol. 1 (1983), 940–945.
74. [74] Mazzone, A., Cusa, C., Mazzucchelli, I., Vezzoli, M., Ottini, E., Pacifici, R., Zuccaro, P., Falcone, C., Increased production of inflammatory cytokines in patients with silent myocardial ischemia. J. Am. Coll. Cardiol. 38 (2001), 1895–1901.
75. [75] Kannel, W.B., Abbott, R.D., Incidence and prognosis of unrecognized myocardial infarction: an update on the framingham study. N. Engl. J. Med. 311 (1984), 1144–1147.
76. [76] Imperi, G.A., Pepine, C.J., Silent myocardial ischemia during daily activities: studies in asymptomatic patients and those with various forms of angina. Cardiol. Clin. 4 (1986), 635–642.
77. [77] Vinik, A.I., Management of neuropathy and foot problems in diabetic patients. Clin. Cornerstone 5 (2003), 38–55.
78. [78] Vinik, A.I., Maser, R.E., Mitchell, B.D., Freeman, R., Diabetic autonomic neuropathy. Diabetes Care 26 (2003), 1553–1579.
79. [79] Chiariello, M., Indolfi, C., Silent myocardial ischemia in patients with diabetes mellitus. Circulation 93 (1996), 2089–2091.
80. [80] Orlander, P.R., Goff, D.C., Morrissey, M., Ramsey, D.J., Wear, M.L., Labarthe, D.R., Nichaman, M.Z., The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-hispanic whites. The Corpus Christi heart project. Diabetes 43 (1994), 897–902.
81. [81] Kannel, W.B., Hjortland, M., Castelli, W.P., Role of diabetes in congestive heart failure: the framingham study. Am. J. Cardiol. 34 (1974), 29–34.
82. [82] Ren, J., Kelley, R.O., Cardiac health in women with metabolic syndrome: clinical aspects and pathophysiology. Obesity 17 (2009), 1114–1123.
83. [83] Barrett-Connor, E., Ferrara, A., Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo study. Diabetes Care 21 (1998), 1236–1239.
84. [84] Huxley, R., Barzi, F., Woodward, M., Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006), 73–78.
85. [85] Ballotari, P., Ranieri, S.C., Luberto, F., Caroli, S., Greci, M., Giorgi Rossi, P., Manicardi, V., Sex differences in cardiovascular mortality in diabetics and nondiabetic subjects: a population-based study (Italy). Int. J. Endocrinol., 2015, 2015, 914057.
86. [86] Barrett-Connor, E.L., Cohn, B.A., Wingard, D.L., Edelstein, S.L., Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo study. JAMA 265 (1991), 627–631.
87. [87] Masding, M.G., Stears, A.J., Burdge, G.C., Wootton, S.A., Sandeman, D.D., Premenopausal advantages in postprandial lipid metabolism are lost in women with type 2 diabetes. Diabetes Care 26 (2003), 3243–3249.
88. [88] Brezinka, V., Padmos, I., Coronary heart disease risk factors in women. Eur. Heart J. 15 (1994), 1571–1584.
89. [89] Kirchberger, I., Heier, M., Kuch, B., Wende, R., Meisinger, C., Sex differences in patient-reported symptoms associated with myocardial infarction (from the population-based Monica/Kora myocardial infarction registry). Am. J. Cardiol. 107 (2011), 1585–1589.
90. [90] Regitz-Zagrosek, V., Sex and gender differences in symptoms of myocardial ischaemia. Eur. Heart J. 32 (2011), 3064–3066.
91. [91] Penno, G., Solini, A., Bonora, E., Fondelli, C., Orsi, E., Zerbini, G., Trevisan, R., Vedovato, M., Gruden, G., Laviola, L., Nicolucci, A., Pugliese, G., Renal, I., Cardiovascular Events study g, Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the Riace Italian multicentre study. J. Intern. Med. 274 (2013), 176–191.
92. [92] Mascarenhas-Melo, F., Marado, D., Palavra, F., Sereno, J., Coelho, A., Pinto, R., Teixeira-Lemos, E., Teixeira, F., Reis, F., Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovasc. Diabetol., 12, 2013, 61.
93. [93] Schwab, K.O., Doerfer, J., Naeke, A., Rohrer, T., Wiemann, D., Marg, W., Hofer, S.E., Holl, R.W., German/Austrian Pediatric DPVI, Influence of food intake, age, gender, HBA1c, and BMI levels on plasma cholesterol in 29,979 children and adolescents with type 1 diabetes-reference data from the german diabetes documentation and quality management system (DPV). Pediatr. Diabetes 10 (2009), 184–192.
94. [94] Soedamah-Muthu, S.S., Fuller, J.H., Mulnier, H.E., Raleigh, V.S., Lawrenson, R.A., Colhoun, H.M., All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. Diabetologia 49 (2006), 660–666.
95. [95] Howangyin, K.Y., Silvestre, J.S., Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 1126–1135.
96. [96] Caporali, A., Meloni, M., Vollenkle, C., Bonci, D., Sala-Newby, G.B., Addis, R., Spinetti, G., Losa, S., Masson, R., Baker, A.H., Agami, R., le Sage, C., Condorelli, G., Madeddu, P., Martelli, F., Emanueli, C., Deregulation of microrna-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123 (2011), 282–291.
97. [97] Salis, M.B., Graiani, G., Desortes, E., Caldwell, R.B., Madeddu, P., Emanueli, C., Nerve growth factor supplementation reverses the impairment, induced by type 1 diabetes, of hindlimb post-ischaemic recovery in mice. Diabetologia 47 (2004), 1055–1063.
98. [98] Das, S., Monteforte, A.J., Singh, G., Majid, M., Sherman, M.B., Dunn, A.K., Baker, A.B., Syndecan-4 enhances therapeutic angiogenesis after hind limb ischemia in mice with type 2 diabetes. Adv. Healthc. Mater. 5 (2016), 1008–1013.
99. [99] Ebrahimian, T.G., Heymes, C., You, D., Blanc-Brude, O., Mees, B., Waeckel, L., Duriez, M., Vilar, J., Brandes, R.P., Levy, B.I., Shah, A.M., Silvestre, J.S., Nadph oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am. J. Pathol. 169 (2006), 719–728.
100. [100] Samuel, S.M., Thirunavukkarasu, M., Penumathsa, S.V., Koneru, S., Zhan, L., Maulik, G., Sudhakaran, P.R., Maulik, N., Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 121 (2010), 1244–1255.
101. [101] Li, C., Lu, C., Zhao, X., Chen, X., Comparison between myocardial infarction and diabetes mellitus damage caused angiogenesis or energy metabolism. Int. J. Clin. Exp. Med. 8 (2015), 22371–22376.
102. [102] Sena, C.M., Pereira, A.M., Seica, R., Endothelial dysfunction – a major mediator of diabetic vascular disease. Biochim. Biophys. Acta 1832 (2013), 2216–2231.
103. [103] Spinetti, G., Kraenkel, N., Emanueli, C., Madeddu, P., Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc. Res. 78 (2008), 265–273.
104. [104] Cannon, R.O. 3rd, Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin. Chem. 44 (1998), 1809–1819.
105. [105] Huang, P.L., Endothelial nitric oxide synthase and endothelial dysfunction. Curr. Hypertens. Rep. 5 (2003), 473–480.
106. [106] Schofield, I., Malik, R., Izzard, A., Austin, C., Heagerty, A., Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 106 (2002), 3037–3043.
107. [107] Johnstone, M.T., Creager, S.J., Scales, K.M., Cusco, J.A., Lee, B.K., Creager, M.A., Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88 (1993), 2510–2516.
108. [108] McVeigh, G.E., Brennan, G.M., Johnston, G.D., McDermott, B.J., McGrath, L.T., Henry, W.R., Andrews, J.W., Hayes, J.R., Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35 (1992), 771–776.
109. [109] Williams, S.B., Cusco, J.A., Roddy, M.A., Johnstone, M.T., Creager, M.A., Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 27 (1996), 567–574.
110. [110] Gobl, C.S., Bozkurt, L., Yarragudi, R., Prikoszovich, T., Tura, A., Pacini, G., Koppensteiner, R., Kautzky-Willer, A., Biomarkers of endothelial dysfunction in relation to impaired carbohydrate metabolism following pregnancy with gestational diabetes mellitus. Cardiovasc. Diabetol., 13, 2014, 138.
111. [111] Lee, S.J., Lee, D.W., Kim, K.S., Lee, I.K., Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes. Diabetes Res. Clin. Pract. 54:Suppl. 2 (2001), S81–92.
112. [112] Campesi, I., Capobianco, G., Dessole, S., Occhioni, S., Montella, A., Franconi, F., Estrogenic compounds have divergent effects on human endothelial progenitor cell migration according to sex of the donor. J. Vasc. Res. 52 (2015), 273–278.
113. [113] Addis, R., Campesi, I., Fois, M., Capobianco, G., Dessole, S., Fenu, G., Montella, A., Cattaneo, M.G., Vicentini, L.M., Franconi, F., Human umbilical endothelial cells (huvecs) have a sex: characterisation of the phenotype of male and female cells. Biol. Sex Differ., 5, 2014, 18.
114. [114] Marra, G., Cotroneo, P., Pitocco, D., Manto, A., Di Leo, M.A., Ruotolo, V., Caputo, S., Giardina, B., Ghirlanda, G., Santini, S.A., Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care 25 (2002), 370–375.
115. [115] Steinberg, H.O., Paradisi, G., Cronin, J., Crowde, K., Hempfling, A., Hook, G., Baron, A.D., Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 101 (2000), 2040–2046.
116. [116] Colhoun, H.M., Rubens, M.B., Underwood, S.R., Fuller, J.H., The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. J. Am. Coll. Cardiol. 36 (2000), 2160–2167.
117. [117] Boudina, S., Abel, E.D., Diabetic cardiomyopathy, causes and effects. Reviews in endocrine & metabolic disorders 11 (2010), 31–39.
118. [118] Ernande, L., Derumeaux, G., Diabetic cardiomyopathy: myth or reality. Arch. Cardiovasc. Dis. 105 (2012), 218–225.
119. [119] Seferovic, P.M., Paulus, W.J., Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur. Heart J. 36 (2015), 1718–1727 1727-1727c.
120. [120] Ren, J., Ceylan-Isik, A.F., Diabetic cardiomyopathy: do women differ from men?. Endocrine 25 (2004), 73–83.
121. [121] Kiencke, S., Handschin, R., von Dahlen, R., Muser, J., Brunner-Larocca, H.P., Schumann, J., Felix, B., Berneis, K., Rickenbacher, P., Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur. J. Heart Fail. 12 (2010), 951–957.
122. [122] Suys, B.E., Katier, N., Rooman, R.P., Matthys, D., Op De Beeck, L., Du Caju, M.V., De Wolf, D., Female children and adolescents with type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyopathy. Diabetes Care 27 (2004), 1947–1953.
123. [123] Adameova, A., Dhalla, N.S., Role of microangiopathy in diabetic cardiomyopathy. Heart Fail. Rev. 19 (2014), 25–33.
124. [124] Meloni, M., Descamps, B., Caporali, A., Zentilin, L., Floris, I., Giacca, M., Emanueli, C., Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice. Diabetes 61 (2012), 229–240.
125. [125] Katare, R.G., Caporali, A., Oikawa, A., Meloni, M., Emanueli, C., Madeddu, P., Vitamin b1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through AKT/PIM-1-mediated survival pathway. Circ. Heart Fail. 3 (2010), 294–305.
126. [126] Legato, M.J., Gelzer, A., Goland, R., Ebner, S.A., Rajan, S., Villagra, V., Kosowski, M., Writing Group for The Partnership for Gender-Specific M, Gender-specific care of the patient with diabetes: review and recommendations. Gend. Med. 3 (2006), 131–158.
127. [127] Chadee, D., Seemungal, T., Pinto Pereira, L.M., Chadee, M., Maharaj, R., Teelucksingh, S., Prevalence of self-reported diabetes, hypertension and heart disease in individuals seeking state funding in Trinidad and Tobago, West Indies. J. Epidemiol. Glob. health 3 (2013), 95–103.
128. [128] Costacou, T., Orchard, T.J., Differential effect of glycemia on the incidence of hypertension by sex: the epidemiology of diabetes complications study. Diabetes Care 36 (2013), 77–83.
129. [129] Stamler, J., Vaccaro, O., Neaton, J.D., Wentworth, D., Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993), 434–444.
130. [130] Bell, D.S., Stroke in the diabetic patient. Diabetes Care 17 (1994), 213–219.
131. [131] Folsom, A.R., Eckfeldt, J.H., Weitzman, S., Ma, J., Chambless, L.E., Barnes, R.W., Cram, K.B., Hutchinson, R.G., Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis risk in communities (ARIC) study investigators. Stroke 25 (1994), 66–73.
132. [132] Mulnier, H.E., Seaman, H.E., Raleigh, V.S., Soedamah-Muthu, S.S., Colhoun, H.M., Lawrenson, R.A., De Vries, C.S., Risk of stroke in people with type 2 diabetes in the UK: a study using the general practice research database. Diabetologia 49 (2006), 2859–2865.
133. [133] Policardo, L., Seghieri, G., Francesconi, P., Anichini, R., Franconi, F., Seghieri, C., Del Prato, S., Gender difference in diabetes-associated risk of first-ever and recurrent ischemic stroke. J. Diabetes Complicat. 29 (2015), 713–717.
134. [134] Peters, S.A., Huxley, R.R., Woodward, M., Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 383 (2014), 1973–1980.
135. [135] Khalangot, M., Hu, G., Tronko, M., Kravchenko, V., Guryanov, V., Gender risk of nonfatal stroke in type 2 diabetic patients differs depending on the type of treatment. J. Women's Health 18 (2009), 97–103.
136. [136] Kothari, V., Stevens, R.J., Adler, A.I., Stratton, I.M., Manley, S.E., Neil, H.A., Holman, R.R., Ukpds 60: risk of stroke in type 2 diabetes estimated by the uk prospective diabetes study risk engine. Stroke 33 (2002), 1776–1781.
137. [137] Mauvais-Jarvis, F., Clegg, D.J., Hevener, A.L., The role of estrogens in control of energy balance and glucose homeostasis. Endocr. Rev. 34 (2013), 309–338.
138. [138] Gupte, A.A., Pownall, H.J., Hamilton, D.J., Estrogen: an emerging regulator of insulin action and mitochondrial function. J. Diabetes Res., 2015, 2015, 916585.
139. [139] Ruegg, J., Cai, W., Karimi, M., Kiss, N.B., Swedenborg, E., Larsson, C., Ekstrom, T.J., Pongratz, I., Epigenetic regulation of glucose transporter 4 by estrogen receptor beta. Mol. Endocrinol. 25 (2011), 2017–2028.
140. [140] Nadal, A., Alonso-Magdalena, P., Soriano, S., Ripoll, C., Fuentes, E., Quesada, I., Ropero, A.B., Role of estrogen receptors alpha, beta and GPER1/GPR30 in pancreatic beta-cells. Front. Biosci. 16 (2011), 251–260.
141. [141] van Genugten, R.E., Utzschneider, K.M., Tong, J., Gerchman, F., Zraika, S., Udayasankar, J., Boyko, E.J., Fujimoto, W.Y., Kahn, S.E., American Diabetes Association GSG, Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes. Diabetes 55 (2006), 3529–3535.
142. [142] Faustini-Fustini, M., Rochira, V., Carani, C., Oestrogen deficiency in men: where are we today?. Eur. J. Endocrinol. Eur. Fed. Endocr. Soc. 140 (1999), 111–129.
143. [143] Szalat, A., Raz, I., Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes. Metab. 10 (2008), 1135–1156.
144. [144] Godsland, I.F., Gangar, K., Walton, C., Cust, M.P., Whitehead, M.I., Wynn, V., Stevenson, J.C., Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metab. Clin. Exp. 42 (1993), 846–853.
145. [145] Ferrara, A., Karter, A.J., Ackerson, L.M., Liu, J.Y., Selby, J.V., Northern California Kaiser Permanente Diabetes, R., Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: the northern California Kaiser Permanente diabetes registry. Diabetes Care 24 (2001), 1144–1150.
146. [146] Andersson, B., Mattsson, L.A., Hahn, L., Marin, P., Lapidus, L., Holm, G., Bengtsson, B.A., Bjorntorp, P., Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82 (1997), 638–643.
147. [147] Kaplan, R.C., Heckbert, S.R., Weiss, N.S., Wahl, P.W., Smith, N.L., Newton, K.M., Psaty, B.M., Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care 21 (1998), 1117–1121.
148. [148] Ryan, A.S., Nicklas, B.J., Berman, D.M., Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 25 (2002), 127–133.
149. [149] Nabulsi, A.A., Folsom, A.R., White, A., Patsch, W., Heiss, G., Wu, K.K., Szklo, M., Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The atherosclerosis risk in communities study investigators. N. Engl. J. Med. 328 (1993), 1069–1075.
150. [150] Ferrara, A., Barrett-Connor, E., Wingard, D.L., Edelstein, S.L., Sex differences in insulin levels in older adults and the effect of body size, estrogen replacement therapy, and glucose tolerance status. The Rancho Bernardo study, 1984–1987. Diabetes Care 18 (1995), 220–225.
151. [151] Navarro, G., Allard, C., Xu, W., Mauvais-Jarvis, F., The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity 23 (2015), 713–719.
152. [152] Corbould, A., Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?. Diabetes Metab. Res. Rev. 24 (2008), 520–532.
153. [153] Selvin, E., Feinleib, M., Zhang, L., Rohrmann, S., Rifai, N., Nelson, W.G., Dobs, A., Basaria, S., Golden, S.H., Platz, E.A., Androgens and diabetes in men: results from the third national health and nutrition examination survey (NHANES III). Diabetes Care 30 (2007), 234–238.
154. [154] Simon, D., Charles, M.A., Lahlou, N., Nahoul, K., Oppert, J.M., Gouault-Heilmann, M., Lemort, N., Thibult, N., Joubert, E., Balkau, B., Eschwege, E., Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 24 (2001), 2149–2151.
155. [155] Tripathy, D., Shah, P., Lakshmy, R., Reddy, K.S., Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm. Metab. Res. 30 (1998), 642–645.
156. [156] Gregg, E.W., Li, Y., Wang, J., Burrows, N.R., Ali, M.K., Rolka, D., Williams, D.E., Geiss, L., Changes in diabetes-related complications in the united states, 1990–2010. N. Engl. J. Med. 370 (2014), 1514–1523.
157. [157] Bae, J.C., Diabetes drugs and cardiovascular safety. Endocrinol. Metab. 31 (2016), 239–244.
158. [158] Maron, B.A., Independence day: separating right ventricular function from pulmonary arterial hypertension in systemic sclerosis. Circulation 133 (2016), 2345–2347.
159. [159] Regensteiner, J.G., Golden, S., Huebschmann, A.G., Barrett-Connor, E., Chang, A.Y., Chyun, D., Fox, C.S., Kim, C., Mehta, N., Reckelhoff, J.F., Reusch, J.E., Rexrode, K.M., Sumner, A.E., Welty, F.K., Wenger, N.K., Anton, B., American Heart Association Diabetes Committee of the Council on L, Cardiometabolic Health CoE, Prevention CoFG, Translational B, Council on H, Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the american heart association. Circulation 132 (2015), 2424–2447.
160. [160] Campesi, I., Carru, C., Zinellu, A., Occhioni, S., Sanna, M., Palermo, M., Tonolo, G., Mercuro, G., Franconi, F., Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex-gender specific manner in healthy young humans. Am. J. Transl. Res. 5 (2013), 497–509.
161. [161] Solberg, L.I., Desai, J.R., O'Connor, P.J., Bishop, D.B., Devlin, H.M., Diabetic patients who smoke: are they different?. Ann. Fam. Med. 2 (2004), 26–32.
162. [162] Anthonisen, N.R., Skeans, M.A., Wise, R.A., Manfreda, J., Kanner, R.E., Connett, J.E., Lung Health Study Research G, The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 142 (2005), 233–239.
163. [163] Register, S.J., Harrington, K.F., Agne, A.A., Cherrington, A.L., Effectiveness of non-primary care-based smoking cessation interventions for adults with diabetes: a systematic literature review. Curr. Diabetes Rep., 16, 2016, 81.
164. [164] Agabio, R., Campesi, I., Pisanu, C., Gessa, G.L., Franconi, F., Sex differences in substance use disorders: focus on side effects. Addict. Biol. 21 (2016), 1030–1042.
165. [165] Forte, P., Kneale, B.J., Milne, E., Chowienczyk, P.J., Johnston, A., Benjamin, N., Ritter, J.M., Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension 32 (1998), 730–734.
166. [166] Shinozaki, K., Kashiwagi, A., Nishio, Y., Okamura, T., Yoshida, Y., Masada, M., Toda, N., Kikkawa, R., Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. Diabetes 48 (1999), 2437–2445.
167. [167] Channon, K.M., Tetrahydrobiopterin: a vascular redox target to improve endothelial function. Curr. Vasc. Pharmacol. 10 (2012), 705–708.
168. [168] Ramprasath, T., Kumar, P.H., Puhari, S.S., Murugan, P.S., Vasudevan, V., Selvam, G.S., L-arginine ameliorates cardiac left ventricular oxidative stress by upregulating enos and NRF2 target genes in alloxan-induced hyperglycemic rats. Biochem. Biophys. Res. Commun. 428 (2012), 389–394.
169. [169] Bendall, J.K., Douglas, G., McNeill, E., Channon, K.M., Crabtree, M.J., Tetrahydrobiopterin in cardiovascular health and disease. Antioxid. Redox Signal. 20 (2014), 3040–3077.
170. [170] Gulati, M., Merz, C.N., New cholesterol guidelines and primary prevention in women. Trends Cardiovasc. Med. 25 (2015), 84–94.
171. [171] Dale, K.M., Coleman, C.I., Shah, S.A., Patel, A.A., Kluger, J., White, C.M., Impact of gender on statin efficacy. Curr. Med. Res. Opin. 23 (2007), 565–574.
172. [172] Pyorala, K., Pedersen, T.R., Kjekshus, J., Faergeman, O., Olsson, A.G., Thorgeirsson, G., Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the scandinavian simvastatin survival study (4s). Diabetes Care 20 (1997), 614–620.
173. [173] Regitz-Zagrosek, V., Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat. Rev. Drug Discov. 5 (2006), 425–438.
174. [174] Culver, A.L., Ockene, I.S., Balasubramanian, R., Olendzki, B.C., Sepavich, D.M., Wactawski-Wende, J., Manson, J.E., Qiao, Y., Liu, S., Merriam, P.A., Rahilly-Tierny, C., Thomas, F., Berger, J.S., Ockene, J.K., Curb, J.D., Ma, Y., Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch. Intern. Med. 172 (2012), 144–152.
175. [175] Paixao, A.R., Ayers, C.R., Berry, J.D., de Lemos, J.A., Khera, A., Atherosclerotic cardiovascular disease prevention: a comparison between the third adult treatment panel and the new 2013 treatment of blood cholesterol guidelines. Circ. Cardiovasc. Qual. Outcomes 7 (2014), 778–779.
176. [176] Mora, S., Glynn, R.J., Hsia, J., MacFadyen, J.G., Genest, J., Ridker, P.M., Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity c-reactive protein or dyslipidemia: results from the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (jupiter) and meta-analysis of women from primary prevention trials. Circulation 121 (2010), 1069–1077.
177. [177] Mehler, P.S., Coll, J.R., Estacio, R., Esler, A., Schrier, R.W., Hiatt, W.R., Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 107 (2003), 753–756.
178. [178] Cadeddu, C., Franconi, F., Cassisa, L., Campesi, I., Pepe, A., Cugusi, L., Maffei, S., Gallina, S., Sciomer, S., Mercuro, G., Working Group of Gender Medicine of Italian Society of C, Arterial hypertension in the female world: pathophysiology and therapy. J. Cardiovasc. Med. 17 (2016), 229–236.
179. [179] Basili, S., Raparelli, V., Proietti, M., Tanzilli, G., Franconi, F., Impact of sex and gender on the efficacy of antiplatelet therapy: the female perspective. J. Atheroscler. Thromb. 22 (2015), 109–125.
180. [180] Patti, G., De Caterina, R., Abbate, R., Andreotti, F., Biasucci, L.M., Calabro, P., Cioni, G., Davi, G., Di Sciascio, G., Golia, E., Golino, P., Malatesta, G., Mangiacapra, F., Marcucci, R., Nusca, A., Parato, V.M., Pengo, V., Prisco, D., Pulcinelli, F., Renda, G., Ricottini, E., Ruggieri, B., Santilli, F., Sofi, F., Zimarino, M., Working Group on Thrombosis of the Italian Society of C, Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A ‘state-of-the-art’ paper. Eur. Heart J. 35 (2014), 2213–2223b.
181. [181] Antiplatelet trialists’ collaboration, Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994), 81–106.
182. [182] Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products; technical amendments. Federal Register, vol. 64, 1999, Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA), 49652–49655 Final rule; technical amendments.
183. [183] Colwell, J.A., American Diabetes, A., Aspirin therapy in diabetes. Diabetes Care 26:Suppl. 1 (2003), S87–88.
184. [184] Stewart, K.J., Hiatt, W.R., Regensteiner, J.G., Hirsch, A.T., Exercise training for claudication. N. Engl. J. Med. 347 (2002), 1941–1951.
185. [185] Angelkort, B., Spurk, P., Habbaba, A., Mahder, M., Blood flow properties and walking performance in chronic arterial occlusive disease. Angiology 36 (1985), 285–292.
186. [186] Money, S.R., Herd, J.A., Isaacsohn, J.L., Davidson, M., Cutler, B., Heckman, J., Forbes, W.P., Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J. Vasc. Surg. 27 (1998), 267–274 discussion 274-265.
187. [187] Anderson, P.L., Gelijns, A., Moskowitz, A., Arons, R., Gupta, L., Weinberg, A., Faries, P.L., Nowygrod, R., Kent, K.C., Understanding trends in inpatient surgical volume: vascular interventions, 1980–2000. J. Vasc. Surg. 39 (2004), 1200–1208.
188. [188] Feinglass, J., McDermott, M.M., Foroohar, M., Pearce, W.H., Gender differences in interventional management of peripheral vascular disease: evidence from a blood flow laboratory population. Ann. Vasc. Surg. 8 (1994), 343–349.
189. [189] Hirsch, A.T., Allison, M.A., Gomes, A.S., Corriere, M.A., Duval, S., Ershow, A.G., Hiatt, W.R., Karas, R.H., Lovell, M.B., McDermott, M.M., Mendes, D.M., Nussmeier, N.A., Treat-Jacobson, D., American Heart Association Council on Peripheral Vascular D, Council on Cardiovascular N, Intervention, Council on Cardiovascular S, Anesthesia, Council on Clinical C, A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation 125 (2012), 1449–1472.
190. [190] DeRubertis, B.G., Vouyouka, A., Rhee, S.J., Califano, J., Karwowski, J., Angle, N., Faries, P.L., Kent, K.C., Percutaneous intervention for infrainguinal occlusive disease in women: equivalent outcomes despite increased severity of disease compared with men. J. Vasc. Surg. 48 (2008), 150–157 discussion 157–158.
191. [191] Pulli, R., Dorigo, W., Pratesi, G., Fargion, A., Angiletta, D., Pratesi, C., Gender-related outcomes in the endovascular treatment of infrainguinal arterial obstructive disease. J. Vasc. Surg. 55 (2012), 105–112.
192. [192] Gloviczki, P., Huang, Y., Oderich, G.S., Duncan, A.A., Kalra, M., Fleming, M.D., Harmsen, W.S., Bower, T.C., Clinical presentation, comorbidities, and age but not female gender predict survival after endovascular repair of abdominal aortic aneurysm. J. Vasc. Surg. 61 (2015), 853–861 e852.
193. [193] Hernandez-Vila, E.A., Peripheral arterial disease in women: the effect of gender on diagnosis and treatment. Tex. Heart Inst. J. 38 (2011), 154–156.
194. [194] Vouyouka, A.G., Egorova, N.N., Salloum, A., Kleinman, L., Marin, M., Faries, P.L., Moscowitz, A., Lessons learned from the analysis of gender effect on risk factors and procedural outcomes of lower extremity arterial disease. J. Vasc. Surg. 52 (2010), 1196–1202.
195. [195] Nesto, R.W., Zarich, S., Acute myocardial infarction in diabetes mellitus: lessons learned from ace inhibition. Circulation 97 (1998), 12–15.
196. [196] Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339 (1998), 229–234.
197. [197] Savage, M.P., Krolewski, A.S., Kenien, G.G., Lebeis, M.P., Christlieb, A.R., Lewis, S.M., Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am. J. Cardiol. 62 (1988), 665–669.
198. [198] Levine, G.N., Bates, E.R., Bittl, J.A., Brindis, R.G., Fihn, S.D., Fleisher, L.A., Granger, C.B., Lange, R.A., Mack, M.J., Mauri, L., Mehran, R., Mukherjee, D., Newby, L.K., O'Gara, P.T., Sabatine, M.S., Smith, P.K., Smith, S.C. Jr., ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: sn update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of st-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation, 2016, 2016.
199. [199] O'Gara, P.T., Kushner, F.G., Ascheim, D.D., Casey, D.E. Jr., Chung, M.K., de Lemos, J.A., Ettinger, S.M., Fang, J.C., Fesmire, F.M., Franklin, B.A., Granger, C.B., Krumholz, H.M., Linderbaum, J.A., Morrow, D.A., Newby, L.K., Ornato, J.P., Ou, N., Radford, M.J., Tamis-Holland, J.E., Tommaso, C.L., Tracy, C.M., Woo, Y.J., Zhao, D.X., Anderson, J.L., Jacobs, A.K., Halperin, J.L., Albert, N.M., Brindis, R.G., Creager, M.A., DeMets, D., Guyton, R.A., Hochman, J.S., Kovacs, R.J., Kushner, F.G., Ohman, E.M., Stevenson, W.G., Yancy, C.W., American College of Cardiology Foundation/American Heart Association Task Force on Practice G, ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 127 (2013), e362–e425.
200. [200] Fonarow, G.C., Abraham, W.T., Cannon, C.P., Gheorghiade, M., Sackner-Bernstein, J.D., Udelson, J.E., Post-Myocardial Infarction Guideline C, Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. Rev. Cardiovasc. Med. 4:Suppl. 3 (2003), S54–59.
201. [201] Fonarow, G.C., Wright, R.S., Spencer, F.A., Fredrick, P.D., Dong, W., Every, N., French, W.J., National Registry of Myocardial Infarction I, Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am. J. Cardiol. 96 (2005), 611–616.
202. [202] Dorian, P., Newman, D., Ace inhibitors after myocardial infarction. N. Engl. J. Med., 328, 1993, 967 author reply 968–969.
203. [203] Stolarz, A.J., Rusch, N.J., Gender differences in cardiovascular drugs. Cardiovasc. Drugs Ther. 29 (2015), 403–410.
204. [204] Franconi, F., Omboni, S., Ambrosioni, E., Reggiardo, G., Campesi, I., Borghi, C., Effects of treatment with zofenopril in men and women with acute myocardial infarction: gender analysis of the smile program. PLoS One, 9, 2014, e111558.
205. [205] Sinnaeve, P., Van de Werf, F., Thrombolytic therapy. State of the art. Thromb. Res. 103:Suppl. 1 (2001), S71–S79.
206. [206] Norris, R.M., Tenecteplase and alteplase in acute myocardial infarction. Lancet 354 (1999), 1818–1819.
207. [207] Vermeer, F., Thrombolytic therapy in patients of female gender. Thromb. Res. 103:Suppl. 1 (2001), S101–104.
208. [208] Nolte, C.H., Heuschmann, P.U., Endres, M., Sex and gender differences in neurology. Sex Gender Asp. Clin. Med., 2012, 169–182.
209. [209] Andersen, H.R., Nielsen, T.T., Rasmussen, K., Thuesen, L., Kelbaek, H., Thayssen, P., Abildgaard, U., Pedersen, F., Madsen, J.K., Grande, P., Villadsen, A.B., Krusell, L.R., Haghfelt, T., Lomholt, P., Husted, S.E., Vigholt, E., Kjaergard, H.K., Mortensen, L.S., Investigators D-, A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N. Engl. J. Med. 349 (2003), 733–742.
210. [210] Kappetein, A.P., Head, S.J., Cabg or pci for revascularisation in patients with diabetes?. Lancet Diabetes Endocrinol. 1 (2013), 266–268.
211. [211] Verma, S., Farkouh, M.E., Yanagawa, B., Fitchett, D.H., Ahsan, M.R., Ruel, M., Sud, S., Gupta, M., Singh, S., Gupta, N., Cheema, A.N., Leiter, L.A., Fedak, P.W., Teoh, H., Latter, D.A., Fuster, V., Friedrich, J.O., Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 1 (2013), 317–328.
212. [212] Santulli, G., Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology, 78, 2012, 840.
213. [213] Ahmed, N., Davalos, A., Eriksson, N., Ford, G.A., Glahn, J., Hennerici, M., Mikulik, R., Kaste, M., Lees, K.R., Lindsberg, P.J., Toni, D., Investigators, S., Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the safe implementation of treatments in stroke international stroke thrombolysis register (SITS-ISTR). Arch. Neurol. 67 (2010), 1123–1130.
214. [214] Galcera-Tomas, J., Melgarejo-Moreno, A., Garcia-Alberola, A., Rodriguez-Garcia, P., Lozano-Martinez, J., Martinez-Hernandez, J., Martinez-Fernandez, S., Prognostic significance of diabetes in acute myocardial infarction. Are the differences linked to female gender?. Int. J. Cardiol. 69 (1999), 289–298.
215. [215] Kaplan, K.L., Fitzpatrick, P., Cox, C., Shammas, N.W., Marder, V.J., Use of thrombolytic therapy for acute myocardial infarction: effects of gender and age on treatment rates. J. Thromb. Thrombolysis 13 (2002), 21–26.
216. [216] Yarzebski, J., Col, N., Pagley, P., Savageau, J., Gore, J., Goldberg, R., Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: a community-wide perspective. Am. Heart J. 131 (1996), 43–50.
217. [217] Rockman, C.B., Saltzberg, S.S., Maldonado, T.S., Adelman, M.A., Cayne, N.S., Lamparello, P.J., Riles, T.S., The safety of carotid endarterectomy in diabetic patients: clinical predictors of adverse outcome. J. Vasc. Surg. 42 (2005), 878–883.
218. [218] Sarac, T.P., Hertzer, N.R., Mascha, E.J., O'Hara, P.J., Krajewski, L.P., Clair, D.G., Karafa, M.T., Ouriel, K., Gender as a primary predictor of outcome after carotid endarterectomy. J. Vasc. Surg. 35 (2002), 748–753.
219. [219] Hegele, R.A., Eliasziw, M., De Angelis, M., Sex, diabetes, and stroke after carotid endarterectomy. Diabetes Care, 26, 2003, 1641.
220. [220] Shaw, L.J., Bugiardini, R., Merz, C.N., Women and ischemic heart disease: evolving knowledge. J. Am. Coll. Cardiol. 54 (2009), 1561–1575.
221. [221] Halvorsen, S., Eritsland, J., Abdelnoor, M., Holst Hansen, C., Risoe, C., Midtbo, K., Bjornerheim, R., Mangschau, A., Gender differences in management and outcome of acute myocardial infarctions treated in 2006–2007. Cardiology 114 (2009), 83–88.
222. [222] Abbate, R., Mannucci, E., Cioni, G., Fatini, C., Marcucci, R., Diabetes and sex: from pathophysiology to personalized medicine. Intern. Emerg. Med. 7:Suppl. 3 (2012), S215–219.
223. [223] Fremont, A.M., Correa-de-Araujo, R., Hayes, S.N., Gender disparities in managed care: it's time for action. Women's Health Issues 17 (2007), 116–119.
224. [224] Chou, A.F., Brown, A.F., Jensen, R.E., Shih, S., Pawlson, G., Scholle, S.H., Gender and racial disparities in the management of diabetes mellitus among medicare patients. Women's Health Issues 17 (2007), 150–161.
225. [225] Rossi, M.C., Cristofaro, M.R., Gentile, S., Lucisano, G., Manicardi, V., Mulas, M.F., Napoli, A., Nicolucci, A., Pellegrini, F., Suraci, C., Giorda, C., Group AMDAS, Sex disparities in the quality of diabetes care: biological and cultural factors may play a different role for different outcomes: a cross-sectional observational study from the amd annals initiative. Diabetes Care 36 (2013), 3162–3168.
226. [226] Giorda, C., Picariello, R., Nada, E., Tartaglino, B., Marafetti, L., Costa, G., Gnavi, R., The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes. PLoS One, 7, 2012, e33839.
227. [227] A desktop guide to type 2 diabetes mellitus. Diabet. Med. 16 (1999), 716–730 European diabetes policy group 1999.
228. [228] Wexler, D.J., Grant, R.W., Meigs, J.B., Nathan, D.M., Cagliero, E., Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 28 (2005), 514–520.
229. [229] Kramer, H.U., Raum, E., Ruter, G., Schottker, B., Rothenbacher, D., Rosemann, T., Szecsenyi, J., Brenner, H., Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the diana study. Cardiovasc. Diabetol., 11, 2012, 88.
230. [230] Barrett-Connor, E., Sex differences in coronary heart disease. Why are women so superior? The 1995 ancel keys lecture. Circulation 95 (1997), 252–264.
231. [231] Arnetz, L., Dorkhan, M., Alvarsson, M., Brismar, K., Ekberg, N.R., Gender differences in non-glycemic responses to improved insulin sensitivity by pioglitazone treatment in patients with type 2 diabetes. Acta Diabetol. 51 (2014), 185–192.
232. [232] Wheeler, S., Moore, K., Forsberg, C.W., Riley, K., Floyd, J.S., Smith, N.L., Boyko, E.J., Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia 56 (2013), 1934–1943.
233. [233] Vlckova, V., Cornelius, V., Kasliwal, R., Wilton, L., Shakir, S., Hypoglycaemia with pioglitazone: analysis of data from the prescription-event monitoring study. J. Eval. Clin. Pract. 16 (2010), 1124–1128.
234. [234] Anichini, R., Cosimi, S., Di Carlo, A., Orsini, P., De Bellis, A., Seghieri, G., Franconi, F., Baccetti, F., Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes Metab. Syndr. Obes. Targets Ther. 6 (2013), 123–129.
235. [235] Trout, K.K., Rickels, M.R., Schutta, M.H., Petrova, M., Freeman, E.W., Tkacs, N.C., Teff, K.L., Menstrual cycle effects on insulin sensitivity in women with type 1 diabetes: a pilot study. Diabetes Technol. Ther. 9 (2007), 176–182.
236. [236] Monami, M., Cresci, B., Colombini, A., Pala, L., Balzi, D., Gori, F., Chiasserini, V., Marchionni, N., Rotella, C.M., Mannucci, E., Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 31 (2008), 199–203.
237. [237] Aiman, U., Najmi, A., Khan, R.A., Statin induced diabetes and its clinical implications. J. Pharmacol. Pharmacother. 5 (2014), 181–185.
238. [238] Burner, E., Menchine, M., Taylor, E., Arora, S., Gender differences in diabetes self-management: a mixed-methods analysis of a mobile health intervention for inner-city latino patients. J. Diabetes Sci. Technol. 7 (2013), 111–118.
239. [239] Chlebowy, D.O., Hood, S., LaJoie, A.S., Gender differences in diabetes self-management among African American adults. West. J. Nurs. Res. 35 (2013), 703–721.
240. [240] Kyriakides, Z.S., Petinakis, P., Kaklamanis, L., Lyras, T., Sbarouni, E., Karayannakos, P., Iliopoulos, D., Kremastinos, D.T., Gender does not influence angiogenesis and arteriogenesis in a rabbit model of chronic hind limb ischemia. Int. J. Cardiol. 92 (2003), 83–91.
241. [241] Peng, X., Wang, J., Lassance-Soares, R.M., Najafi, A.H., Sood, S., Aghili, N., Alderman, L.O., Panza, J.A., Faber, J.E., Wang, S., Epstein, S.E., Burnett, M.S., Gender differences affect blood flow recovery in a mouse model of hindlimb ischemia. Am. J. Physiol. Heart Circ. Physiol. 300 (2011), H2027–2034.
242. [242] Sieveking, D.P., Lim, P., Chow, R.W., Dunn, L.L., Bao, S., McGrath, K.C., Heather, A.K., Handelsman, D.J., Celermajer, D.S., Ng, M.K., A sex-specific role for androgens in angiogenesis. J. Exp. Med. 207 (2010), 345–352.
243. [243] Kinnaird, T., Stabile, E., Burnett, M.S., Shou, M., Lee, C.W., Barr, S., Fuchs, S., Epstein, S.E., Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109 (2004), 1543–1549.
244. [244] Kalka, C., Masuda, H., Takahashi, T., Kalka-Moll, W.M., Silver, M., Kearney, M., Li, T., Isner, J.M., Asahara, T., Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 3422–3427.
245. [245] Antonio, N., Fernandes, R., Soares, A., Soares, F., Lopes, A., Carvalheiro, T., Paiva, A., Pego, G.M., Providencia, L.A., Goncalves, L., Ribeiro, C.F., Reduced levels of circulating endothelial progenitor cells in acute myocardial infarction patients with diabetes or pre-diabetes: accompanying the glycemic continuum. Cardiovasc. Diabetol., 13, 2014, 101.
246. [246] Fadini, G.P., Miorin, M., Facco, M., Bonamico, S., Baesso, I., Grego, F., Menegolo, M., de Kreutzenberg, S.V., Tiengo, A., Agostini, C., Avogaro, A., Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45 (2005), 1449–1457.
247. [247] Loomans, C.J., de Koning, E.J., Staal, F.J., Rookmaaker, M.B., Verseyden, C., de Boer, H.C., Verhaar, M.C., Braam, B., Rabelink, T.J., van Zonneveld, A.J., Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53 (2004), 195–199.
248. [248] Tamarat, R., Silvestre, J.S., Le Ricousse-Roussanne, S., Barateau, V., Lecomte-Raclet, L., Clergue, M., Duriez, M., Tobelem, G., Levy, B.I., Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am. J. Pathol. 164 (2004), 457–466.
249. [249] Jarajapu, Y.P., Grant, M.B., The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ. Res. 106 (2010), 854–869.
250. [250] Tepper, O.M., Galiano, R.D., Capla, J.M., Kalka, C., Gagne, P.J., Jacobowitz, G.R., Levine, J.P., Gurtner, G.C., Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106 (2002), 2781–2786.
251. [251] Bai, Y., Sun, T., Ye, P., Age, gender and diabetic status are associated with effects of bone marrow cell therapy on recovery of left ventricular function after acute myocardial infarction: a systematic review and meta-analysis. Ageing Res. Rev. 9 (2010), 418–423.
252. [252] Broqueres-You, D., Lere-Dean, C., Merkulova-Rainon, T., Mantsounga, C.S., Allanic, D., Hainaud, P., Contreres, J.O., Wang, Y., Vilar, J., Virally, M., Mourad, J.J., Guillausseau, P.J., Silvestre, J.S., Levy, B.I., Ephrin-b2-activated peripheral blood mononuclear cells from diabetic patients restore diabetes-induced impairment of postischemic neovascularization. Diabetes 61 (2012), 2621–2632.
253. [253] Fadini, G.P., de Kreutzenberg, S., Albiero, M., Coracina, A., Pagnin, E., Baesso, I., Cignarella, A., Bolego, C., Plebani, M., Nardelli, G.B., Sartore, S., Agostini, C., Avogaro, A., Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 997–1004.
254. [254] Raval, Z., Losordo, D.W., Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ. Res. 112 (2013), 1288–1302.
255. [255] Ruiz-Salmeron, R., de la Cuesta-Diaz, A., Constantino-Bermejo, M., Perez-Camacho, I., Marcos-Sanchez, F., Hmadcha, A., Soria, B., Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia. Cell Transplant. 20 (2011), 1629–1639.
256. [256] Gu, H.F., Alvarsson, A., Efendic, S., Brismar, K., Sox2 has gender-specific genetic effects on diabetic nephropathy in samples from patients with type 1 diabetes mellitus in the GoKinD study. Gend. Med. 6 (2009), 555–564.
257. [257] Caporali, A., Emanueli, C., Microrna regulation in angiogenesis. Vasc. Pharmacol. 55 (2011), 79–86.
258. [258] Asli, N.S., Pitulescu, M.E., Kessel, M., Micrornas in organogenesis and disease. Curr. Mol. Med. 8 (2008), 698–710.
259. [259] Suarez, Y., Fernandez-Hernando, C., Pober, J.S., Sessa, W.C., Dicer dependent micrornas regulate gene expression and functions in human endothelial cells. Circ. Res. 100 (2007), 1164–1173.
260. [260] Suarez, Y., Fernandez-Hernando, C., Yu, J., Gerber, S.A., Harrison, K.D., Pober, J.S., Iruela-Arispe, M.L., Merkenschlager, M., Sessa, W.C., Dicer-dependent endothelial micrornas are necessary for postnatal angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 14082–14087.
261. [261] Kuehbacher, A., Urbich, C., Zeiher, A.M., Dimmeler, S., Role of dicer and drosha for endothelial microrna expression and angiogenesis. Circ. Res. 101 (2007), 59–68.
262. [262] Yang, W.J., Yang, D.D., Na, S., Sandusky, G.E., Zhang, Q., Zhao, G., Dicer is required for embryonic angiogenesis during mouse development. J. Biol. Chem. 280 (2005), 9330–9335.
263. [263] Guay, C., Roggli, E., Nesca, V., Jacovetti, C., Regazzi, R., Diabetes mellitus, a microrna-related disease?. Transl. Res. J. Lab. Clin. Med. 157 (2011), 253–264.
264. [264] Li, Y., Song, Y.H., Li, F., Yang, T., Lu, Y.W., Geng, Y.J., Microrna-221 regulates high glucose-induced endothelial dysfunction. Biochem. Biophys. Res. Commun. 381 (2009), 81–83.
265. [265] Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.L., Segnalini, P., Gu, Y., Dalton, N.D., Elia, L., Latronico, M.V., Hoydal, M., Autore, C., Russo, M.A., Dorn, G.W. 2nd, Ellingsen, O., Ruiz-Lozano, P., Peterson, K.L., Croce, C.M., Peschle, C., Condorelli, G., Microrna-133 controls cardiac hypertrophy. Nat. Med. 13 (2007), 613–618.
266. [266] Sharma, S., Eghbali, M., Influence of sex differences on microrna gene regulation in disease. Biol. Sex Differ., 5, 2014, 3.
267. [267] Kuokkanen, S., Chen, B., Ojalvo, L., Benard, L., Santoro, N., Pollard, J.W., Genomic profiling of micrornas and messenger rnas reveals hormonal regulation in microrna expression in human endometrium. Biol. Reprod. 82 (2010), 791–801.
268. [268] Paris, O., Ferraro, L., Grober, O.M., Ravo, M., De Filippo, M.R., Giurato, G., Nassa, G., Tarallo, R., Cantarella, C., Rizzo, F., Di Benedetto, A., Mottolese, M., Benes, V., Ambrosino, C., Nola, E., Weisz, A., Direct regulation of microrna biogenesis and expression by estrogen receptor beta in hormone-responsive breast cancer. Oncogene 31 (2012), 4196–4206.
269. [269] Waltering, K.K., Porkka, K.P., Jalava, S.E., Urbanucci, A., Kohonen, P.J., Latonen, L.M., Kallioniemi, O.P., Jenster, G., Visakorpi, T., Androgen regulation of micro-rnas in prostate cancer. Prostate 71 (2011), 604–614.
270. [270] Wang, Y.T., Tsai, P.C., Liao, Y.C., Hsu, C.Y., Juo, S.H., Circulating micrornas have a sex-specific association with metabolic syndrome. J. Biomed. Sci., 20, 2013, 72.
271. [271] Argyropoulos, C., Wang, K., Bernardo, J., Ellis, D., Orchard, T., Galas, D., Johnson, J.P., Urinary microrna profiling predicts the development of microalbuminuria in patients with type 1 diabetes. J. Clin. Med. 4 (2015), 1498–1517.
272. [272] Floris, I., Descamps, B., Vardeu, A., Mitic, T., Posadino, A.M., Shantikumar, S., Sala-Newby, G., Capobianco, G., Mangialardi, G., Howard, L., Dessole, S., Urrutia, R., Pintus, G., Emanueli, C., Gestational diabetes mellitus impairs fetal endothelial cell functions through a mechanism involving microrna-101 and histone methyltransferase enhancer of zester homolog-2. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 664–674.
273. [273] Rahimi, G., Jafari, N., Khodabakhsh, M., Shirzad, Z., Dogaheh, H.P., Upregulation of microrna processing enzymes drosha and dicer in gestational diabetes mellitus. Gynecol. Endocrinol. 31 (2015), 156–159.
274. [274] Chen, G.C., Qin, L.Q., Ye, J.K., Leptin levels and risk of type 2 diabetes: gender-specific meta-analysis. Obes. Rev. 15 (2014), 134–142.
275. [275] Li, S., Shin, H.J., Ding, E.L., van Dam, R.M., Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302 (2009), 179–188.
276. [276] Daniels, L.B., Maisel, A.S., Cardiovascular biomarkers and sex: the case for women. Nat. Rev. 12 (2015), 588–596.
277. [277] Melander, O., Maisel, A.S., Almgren, P., Manjer, J., Belting, M., Hedblad, B., Engstrom, G., Kilger, U., Nilsson, P., Bergmann, A., Orho-Melander, M., Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 308 (2012), 1469–1475.
278. [278] Abbasi, A., Corpeleijn, E., Meijer, E., Postmus, D., Gansevoort, R.T., Gans, R.O., Struck, J., Hillege, H.L., Stolk, R.P., Navis, G., Bakker, S.J., Sex differences in the association between plasma copeptin and incident type 2 diabetes: the prevention of renal and vascular endstage disease (prevend) study. Diabetologia 55 (2012), 1963–1970.
279. [279] Wannamethee, S.G., Welsh, P., Papacosta, O., Lennon, L., Whincup, P.H., Sattar, N., Copeptin, insulin resistance, and risk of incident diabetes in older men. J. Clin. Endocrinol. Metab. 100 (2015), 3332–3339.
280. [280] Gomez-Serrano, M., Camafeita, E., Garcia-Santos, E., Lopez, J.A., Rubio, M.A., Sanchez-Pernaute, A., Torres, A., Vazquez, J., Peral, B., Proteome-wide alterations on adipose tissue from obese patients as age-, diabetes- and gender-specific hallmarks. Sci. Rep., 6, 2016, 25756.
281. [281] Choi, M., Choi, J.W., Chaudhari, H.N., Aseer, K.R., Mukherjee, R., Yun, J.W., Gender-dimorphic regulation of skeletal muscle proteins in streptozotocin-induced diabetic rats. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 31 (2013), 408–420.
282. [282] Kavanagh, A., Bentley, R.J., Turrell, G., Shaw, J., Dunstan, D., Subramanian, S.V., Socioeconomic position, gender, health behaviours and biomarkers of cardiovascular disease and diabetes. Soc. Sci. Med. 71 (2010), 1150–1160.